Navigation Links
Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
Date:8/20/2007

WALTHAM, Mass., Aug. 20 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that certain executive officers, including Marijn E. Dekkers, president and chief executive officer, are adopting stock- trading programs under Securities and Exchange Commission (SEC) Rule 10b5-1 covering the future sale of company stock. Mr. Dekkers, who exercised options for and sold 300,000 shares over August 15-17, 2007, has adopted a plan for the future sale of up to an additional 780,000 shares, which he would acquire upon the exercise of stock options granted in 2002. Mr. Dekkers entered into this program in order to diversify his financial holdings, although he will continue to have a significant ownership interest in the company. After selling these shares, Mr. Dekkers would own shares, or share equivalents, and hold options totaling 1,860,378 shares.

These trading programs are based on SEC Rule 10b5-1, which protects company executives from possible claims of insider trading by permitting them to buy or sell a predetermined amount of their company's shares, as set forth in a planned acquisition or divestiture program that was adopted when the insider did not possess any material non-public information.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com .

Media Contact Information: Investor Contact Information:

Lori Gorski Ken Apicerno

Phone: 781-622-1242 Phone: 781-622-1111

E-mail: lori.gorski@thermofisher.com E-mail: ken.apicerno@thermofisher.com

Website: http://www.thermofisher.com


'/>"/>
SOURCE Thermo Fisher Scientific Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Normalizing cDNA libraries using the EppendorfThermomixer
2. Rapid PCR* Using Active Tube Temperature Control On Thermos PCR Machines
3. A simple method to sequence from bacterial colonies using [a-33P] radiolabeled ddNTPs and Thermo Sequenase
4. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
5. UW-Madisons Beebe wins scientific award
6. Researchers say scientific reporting needs more perspective, less hype
7. Wisconsin stands at the center of scientific efforts to avert flu epidemics
8. Growth prompts new location for scientific instrument manufacturer
9. UW stem cell guru outlines scientific and political future
10. Wisconsin biotech sector featured in scientific magazine
11. Scientific Protein Laboratories Acquired by New York firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... and GREENWICH, Conn. , Feb. ... firm focused on venture growth investments in biotechnology ... Josh Richardson , M.D. to Managing Director. ... biotechnology companies.  He is a board observer at ... in Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, ...
(Date:2/16/2017)... CALABASAS, Calif. , Feb. 16, 2017 /PRNewswire/ ... on developing groundbreaking therapies to treat severe neurological ... in children treated with AGT-181, the company,s investigational ... syndrome (also known as mucopolysaccharidosis type I, or ... Phase 2 proof-of-concept (POC) study, presented today at ...
(Date:2/16/2017)...   Capricor Therapeutics, Inc. (NASDAQ: ... first-in-class biological therapies for cardiac and other medical ... terminate its license agreement with the Mayo Clinic ... "Our decision to return these rights ... efforts to advance our core cell and exosome-based ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 ... Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor ... of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... for both public and private sectors. Continue Reading ... ...
(Date:1/18/2017)... 18, 2017 MedNet Solutions , ... the entire spectrum of clinical research, is proud ... year for the organization in terms of corporate ... eClinical products and services. The company,s exceptional achievements ... of iMedNet ™ ...
Breaking Biology News(10 mins):